an old release, from 6/4/98.......
New Brunswick Scientific Co., Inc. and W.H. Promation Ltd. Form Joint Venture
EDISON, N.J., June 4 /PRNewswire/ -- New Brunswick Scientific Co., Inc.
(NBS) (Nasdaq: NBSC), today reported it has entered into a joint venture with
W.H. Promation Ltd. The joint venture, which is called NBS Projects, brings
together NBS' bioprocess equipment design and manufacturing skills with the
engineering and full process execution prowess of W.H. Promation, an
engineering company with extensive experience in implementing large
process-related projects.
NBS Projects, which is based in the United Kingdom, specializes in
bioprocess system design, construction, commissioning and validation for the
worldwide pharmaceutical and biotechnology industries, and provides a broad
range of services including feasibility and front-end studies, process as well
as facility design and layout, clean room design and implementation,
procurement, installation, construction, commissioning and validation.
NBS and Promation which have previously collaborated on a number of
projects, recently completed a full FDA-validated, cGMP human therapeutics
production facility which is based around a bioreactor process with all the
associated ancillary upstream and downstream process equipment. The companies
managed the entire project including installing and commissioning the clean
room suites and equipment to provide a totally integrated facility.
Ezra Weisman, President and CEO of NBS said: "Whatever a customer's
requirements, from developing a turnkey bioprocess production facility to
modifying a downstream process, NBS Projects has the unique blend of
technological manufacturing expertise and full project management capability
to deliver a complete project on time and within a specified budget."
New Brunswick Scientific Co., Inc. designs and manufactures a wide variety
of research equipment and scientific instruments for the life sciences.
The Company, through DGI BioTechnologies, its majority owned drug lead
discovery operation, is also developing a proprietary process which is
expected to result in the discovery of novel therapeutics by generating
biologically active drug leads for known pharmaceutical targets.
This press release includes statements which may constitute
forward-looking statements made pursuant to the safe harbor provision of the
Private Securities Litigation Reform Act of 1995. This information may
involve risks and uncertainties including without limitation, risks relating
to the development by DGI of its technology, that could cause actual results
to differ materially from the forward-looking statements. Although the
Company believes that the expectations reflected in such forward-looking
statements are based on reasonable assumptions, such statements are subject to
risks and uncertainties that could cause actual results to differ materially
from those projected.
SOURCE New Brunswick Scientific Co., Inc.
CONTACT: Samuel Eichenbaum, Vice President, Finance of New
Brunswick Scientific Co., Inc., 732-287-1200, Ext. 2239, or
same@nbsc.com |
